This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Myovant Sciences 향후 성장
Future 기준 점검 5/6
핵심 정보
59.0%
이익 성장률
60.27%
EPS 성장률
| Biotechs 이익 성장 | 25.2% |
| 매출 성장률 | 27.6% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 10 Mar 2023 |
최근 향후 성장 업데이트
Recent updates
Seeking Alpha • Jan 26
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.56 beats by $0.08. Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M. Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement totaled $315.7 million in the aggregate as of December 31, 2022, and consisted of $274.4 million of cash, cash equivalents, and marketable securities and $41.3 million of available borrowing capacity under the Sumitomo Pharma Loan Agreement.Seeking Alpha • Oct 25
Not The Buyout Offer That Myovant Shareholders Hoped For
Summary The backbone of the company is Relugolix, a product in a platform already approved in three indications and planned to be investigated in additional indications. Relugolix has the potential to become the new standard of care in each indication and to generate billions in sales. The $4.2 billion deal with Pfizer validates this potential. Majority owner Sumitovant Biopharma also sees the huge potential, offering $27 per share in a takeover bid. The deal is expected to close in early 2023. Due to the low risk of a rejection of the offer, the share becomes interesting for arbitrageurs. Even though almost a year has passed since my last article on Myovant (MYOV), I have nonetheless always followed the company closely. My initial interest in Myovant was triggered by the deal with Pfizer (PFE) and my conviction in Myovant's pipeline. The pipeline conviction has been further strengthened in recent months. Not only has Relugolix been approved in all three indications, but product sales have accelerated in recent months, indicating the huge revenue potential. Another bonus, but not included in the investment thesis, was the strong interest from Myovant's majority owner Sumitovant Biopharma. The strong interest has now been confirmed by the offer to acquire all outstanding shares of Myovant for $27 per share. With Sumitovant Biopharma's buyout offer, I conclude my coverage by addressing recent developments and presenting a valuation approach to evaluate the offer. Business of Myovant Logo of Myovant Science (Source: Company Homepage) I like to start my articles with a brief company overview to give new investors some initial guidance. The company was founded in 2016, is headquartered in Basel, Switzerland, and focuses on the two focus areas of hormone-sensitive cancers and women's health. Over the past 6 years, the company has successfully completed five Phase 3 clinical trials in these areas, resulting in three regulatory approvals by the FDA in the US. In 2021, Myovant also established itself as a commercial company in the market with its highly differentiated therapies in high-growth categories. Myovant's ambition remains to establish its current commercially available brands, together with its top-tier partners, as the new standard of care in the market, and simultaneously maximizing future growth opportunities by expanding its pipeline. The Pipeline Does Not Reflect the Full Potential Since my last article, Myovant has continued to advance its pipeline. The clinical development programs were successfully completed and resulted in approvals. As a result, it is increasingly important to question how Myovant can unlock future growth opportunities. Both products show platform potential (Source: Company Homepage) The backbone of the company is Relugolix, a product as a pipeline, serving as platform therapy and approved in three indications. In addition to approvals in advanced prostate cancer (APC) and uterine fibroids (UT), the FDA recently approved Relugolix in endometriosis in August of this year. Additional approvals will follow in the coming months. Along with the submission of the Marketing Authorization Application (MAA) in Europe for endometriosis, the submission of a New Drug Application (NDA) in Canada is also planned across the three indications in 2022. Enhancing the Label of Relugolix In addition to the approval processes, Myovant is currently focusing primarily on other life cycle activities and on enhancing the labeling of relugolix. For example, Myovant has already submitted a supplemental New Drug Application (sNDA) to adjust the current limitation of using Myfembree only for 2 years in UT. The sNDA is based on two-year data from the LIBERTY randomized withdrawal study. The study results show the longer term benefits and demonstrate very strong bone mineral density (BMD) results, which are the main reason for the two year treatment limitation. The FDA will make a decision on the label adjustment by its PDUFA date of January 29, 2023. Following the FDA decision, an sNDA is expected to be submitted for a label adjustment in endometriosis. In an effort to further differentiate Relugolix from the competition and target a larger patient population, Relugolix is being evaluated for contraceptive efficacy in a Phase 3 study called SERENE. Myovant is confident in the success of the study based on the data to date and expects to unlock significant value and to better serve the women's needs. For women seeking hormonal treatment for their uterine fibroids or endometriosis, one challenge is having to use barrier method contraception, as simultaneous use of both hormonal therapies increases the risk of serious and severe adverse events, including thromboembolic events. Additional trials are also being conducted for Relugolix in APC, for example to prove its safety in combination therapies with other agents. Results of this trial may be published as early as the end of 2022. Indication Expansions for Relugolix and MVT-602 Myovant believes the indication expansion for Relugolix, in both oncology and women's health, is the second major area providing sustainable growth opportunities. In the further course of the fiscal year, the multiple targets for indication expansions will be defined in close collaboration with partner Pfizer and then communicated to the market. In my last article, I already mentioned that GnRH modulation has been validated in previous studies, for example in breast cancer. I can also imagine a treatment approach in ovarian cancer or bladder cancer. In addition to Relugolix, a second product is in the clinical development pipeline, MVT-602. Myovant expects to establish a development pathway for MVT-602 by the end of the fiscal year. MVT-602 is another potential platform therapy that has been investigated in the early stages primarily in the context of fertility. However, due to its multiple sites of action, other exciting potential opportunities are currently being evaluated. Sales Progress Originally, I wanted to wait for the publication of the Q2 numbers in order to give an up-to-date assessment. However, given Sumitovant's offer, the conference call was cancelled, which is why I intend to focus more on the strategic relevance and the outlook. Especially the sales ramp-up of ORGOVYX is very strong. Not only is the quarterly sequential demand volume growth of 26% impressive, but also the fact that 60% of patients start their androgen deprivation therapy (ADT) therapy with ORGOVYX. In my opinion, ORGOVYX will be able to maintain that growth rate in the coming months. On the one hand, ADT represents the basic therapy for ADT. On the other hand, 300,000 patients are treated with ADT annually, so the untapped market potential is enormous. MYFEMBREE sales will really take off in the coming months. With approval in endometriosis, additional synergies can be exploited and Myovant will be able to benefit from several factors. First, Myovant benefits from the large overlap among prescribers. Prescribers have already had a positive experience with MYFEMBREE in UT. Only 6 months after launch, MYFEMBREE has become the market leader in UT and Myovant has increased the GnRH antagonist class by more than 180%. MYFEMBREE is the main driver of GnRH antagonist growth in UT. (Source: Company Presentation) Myovant intends to apply this success to the market in endometriosis. Endometriosis represents a patient population twice as large with an even higher unmet medical need. For this reason, competitor AbbVie (ABBV) generates the majority of its annual sales of nearly $150 million with elagolix in endometriosis. If Myovant manages to more than double this market as well within one year and reaches a 50% market share, this would correspond to annualized revenues of about $200 million. Due to the high overlap in prescribers, Myovant will also not need to expand its current sales force of 100 employees. Financial Assessment Myovant is in a strong financial position. Due to the milestone payments from the Pfizer deal, its cash position was maintained at a reasonably level over the last years despite the high expenses. The current cash balance of $385 million combined with the committed available financing of $41.3 million will enable Myovant to both further intensify the commercialization of Orgovyx and Myfembree and to advance its pipeline. Cash at the end of Q2 should be slightly higher than at the end of Q1 due to the $100 million milestone payment from Pfizer. We don't anticipate any near-term raise of any additional capital. Source: Mehra, Baird Global Healthcare Conference Financial Overview of Myovant (Source: Author's Chart) Due to the loan from Sumitovant of up to $400 million, of which $358.7 million has been drawn to date, liabilities exceed the current cash balance, resulting in a negative net cash balance. While interest is paid quarterly, the terms of the agreement require Myovant to repay the entire loan by the end of 2024. In my opinion, the end of this loan will result in a new financing arrangement. In addition to the net revenues from the commercialization of Relugolix, Myovant is eligible to receive royalties and milestone payments from its partners. Myovant is entitled to receive up to $3.7 billion in regulatory and sales related milestone payments. The milestone payments show significant potential (Source: Author's Chart) While $15 million is due upon approval of Relugolix in endometriosis in the EU, all other milestone payments are not further specified. Consequently, it is difficult to value these milestone payments as no conclusions can be drawn on the likelihood and timing. If all details were known, milestone payments could be calculated using the net present value method. According to management, some milestone payments are considered to be well achievable, while others are more challenging to achieve. Once the milestone has been achieved, the milestone payments are paid out a few days after the end of the calendar quarter. Tiered sales milestones after hitting specific thresholds up to $2.5 billion in net sales for prostate cancer and also for the combined women's health indications. Source: Mark Terry, Biospace I will explicitly point out once again that details on milestone payments have not been disclosed. Nevertheless, I would like to visualize the structure of these milestone payments in an illustration with fictitious numbers. Exemplary presentation of potential Pfizer sales milestones (Source: Author's Chart) The only negative aspect in the quarterly numbers are still the costs, which are far too high compared to the revenues. Expenditures of more than $100 million are offset by product sales of only about $30 million. This calculation already takes into account the royalty payments to Takeda (TAK) and the profit sharing agreement with Pfizer. For this reason, Myovant remains heavily loss-making, and the threshold to profitability is out of sight. Even if the high quarterly growth rates in net product sales can be maintained, Myovant will not be profitable until mid-2024, according to my calculation. The road to profitability is still long (Source: Author's Chart) Although Myovant will not be profitable in the coming quarters, the current cash balance is still sufficient to fund the company and drive both its commercial strategy and clinical development. Approach to a Fair Value In my last article, I already discussed the intense interest of Sumitovant and provided background information on a buy-out speculation. In early October, this intense interest was confirmed by a preliminary, non-binding proposal from Sumitovant to acquire all remaining shares from Myovant. In total, the offer to purchase all remaining shares of Myovant includes a transaction volume of approximately $2.4 billion. However, a committee specially installed for this purpose has rejected the offer as it significantly undervalues the company. For this reason, I will set out an approach to calculate a fair value and summarize the key value drivers. The cash component is currently negligible. Although the acquirer of Myovant can access the complete cash balance, the debts are also transferred to the acquirer. The most relevant value driver at present is the pipeline with the approved product Relugolix. I have summarized the most important facts in the following table: Summarizing the value of Relugolix (Source: Author's Chart) The current therapies available on the market have large shortcomings and do not fully meet the needs of patients. For this reason, Relugolix has an enormous potential to become the new standard-of-care therapy. Orgovyx can achieve conservative peak sales of over $1 billion. The currently available therapies inferior to Relugolix turn over just under $2 billion annually. It is worth noting that these therapies have been on the market for a long time and no longer have patent protection. Nevertheless, these therapies have tremendous value. For example, Medigene sold a 2% revenue share in Eligard with a remaining patent term of 10 years for about $17.7 million, meaning that Eligard alone was valued at almost $900 million at that time. With annual therapy costs of about $27,700, a small number of 40,000 patients treated with Orgovyx is enough to achieve blockbuster status and to generate sales beyond $1 billion. If we annualize the steady growing quarterly sales of Orgovyx, Myovant reaches $200 million in annual sales after only 2 years on the market. The market potential in women's health is similarly large, although a shift in the treatment paradigm is required and has been the biggest problem to date. The high medical need is reflected in the high number of surgical procedures; approximately 350,00 women have their hysterectomies removed each year due to the severity of symptoms and limited therapeutic benefit. There is a relevant competitor in AbbVie, offering a similar but inferior product in terms of simplicity and tolerability.Seeking Alpha • Oct 03
Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Myovant Sciences (NYSE:MYOV) said a special committee of its board rejected a $22.75/share offer from Sumitovant Biopharma to buy the remaining shares of the biopharma company it doesn't already own. Sumitovant currently holds approximately 52% of the outstanding shares of Myovant (MYOV). The offer represents a 27% premium to MYOV's closing price on Friday. Myovant (MYOV) board's special committee determined that the offer "significantly undervalues" the company and is not in the best interest of the company or its minority shareholders, according to a statement. The special committee remains open to considering any improved proposal that reflects the full and fair value of the company The special committee retained Goldman Sachs as its financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP as its legal advisor to assist with its review of the proposal. Myovant Sciences (MYOV) short interest is 7.6%. Last month Myovant Sciences (MYOV) was upgraded to outperform at SVB following additional Myfembree indication.Seeking Alpha • Sep 20
Women Can Thank Pfizer And Myovant For MYFEMBREE
Summary The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there are many opportunities in women's health drug development. Myovant currently appears to be overvalued because of uncertainties around its financial condition. In brief, what happened In August, Pfizer Inc. (PFE) and Myovant Sciences Ltd. (MYOV) announced that the FDA approved MYFEMBREE, a drug for treating moderate to severe pain associated with endometriosis. The drug is taken once daily for up to 24 months and is among hormonal therapies. The pill's approval is based on positive data from the phase 3 SPIRIT program of more than 1,200 women, which demonstrated a "reduction in menstrual pain and nonmenstrual pelvic pain with an average bone mineral density loss of less than 1% from baseline at one year of treatment." The SPIRIT program, divided into SPIRIT1 and SPIRIT2, achieved their respective co-primary endpoints: in both studies, 75% of women reduced dysmenorrhea compared with 27% and 30% of women in the placebo groups. In addition, MYFEMBREE also demonstrated a significant reduction in nonmenstrual pelvic pain in 59% and 66% of women, compared with 40% and 43% of women in the placebo groups. How big is the market for endometriosis? Endometriosis affects about 5%-10% of women of reproductive age, and the condition is often underestimated because it is diagnosed based on symptoms and can sometimes be confused with other conditions. The endometriosis market in 2020 was worth $1.8 billion, and analysts expect it to reach $2.2 billion in 2027. Of this $2 billion, $1.4 billion will be occupied by hormonal therapies, such as MYFEMBREE or Orilissa. The U.S. market is the largest and was worth $524 million in 2020, while China, the second largest market, could be worth $400 million by 2024. Analysts expect MYFEMBREE to cross the $1 billion barrier in 2028. Who are the main competitors Among MYFEMBREE's main competitors is Orilissa, a drug developed by AbbVie (ABBV) and Neurocrine Biosciences (NBIX) that received FDA approval in 2018. As with the drug from Pfizer and Myovant Sciences, Orilissa is also a hormonal drug taken orally. Still, MYFEMBREE is indicated for managing heavy menstrual bleeding and affects pain management. Orilissa is specifically for pain management. Another drug similar to MYFEMBREE is Oriahnn (which, like Orilissa, contains elagolix, estradiol and norethindrone acetate). In Europe and the UK, Linzagolix was recently approved for treating moderate to severe pain associated with endometriosis. From phase 3, Linzagolix has a significant advantage over MYFEMBREE and Orilissa in minimizing adverse effects such as loss of bone density. However, the drug was rejected by the FDA due to significant shortcomings in the NDA that prompted ObsEva (OBSV) to return the license to its discoverer, the Japanese company Kissei, because of the high costs the company would incur for further trials. Risks The principal risks of Pfizer's new drug are twofold:Seeking Alpha • Aug 29
Myovant Sciences: Regulatory Overhang Cleared
Summary Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stock but now comes the harder part - commercialization of Myfembree in this indication. Orgovyx continues to produce strong growth with 22% sequential increase in net sales in the second calendar quarter of 2022. With the stock rallying nearly 50% since April, Myovant is not as attractively valued, but there's still upside ahead. The approval of Myfembree makes Myovant more attractive to acquirers, primarily to majority owner Sumitomo and partner Pfizer. Shares of Myovant Sciences (MYOV) rallied nearly 50% since my April article and 30% since my update in July. This was the result of the company executing on the commercial front and, more importantly, the clearance of the regulatory overhang in the form of Myfembree’s approval for the treatment of endometriosis. The company now has a clear road to execute the launch of Myfembree in the more popular indication, at least based on the sales of AbbVie’s (ABBV) Orilissa/Oriahnn. Myfembree’s approval for endometriosis This was an overhang on the stock due to the deficiency letter the company received in April, but the subsequent three-month PDUFA extension made the situation a bit clearer, and the stock rallied as a result. In my previous article, I noted that any issue related to Myfembree’s negative impact on bone mineral density can be addressed with appropriate product labeling, the same way it was addressed in the case of Orilissa, and the same way it was addressed with Myfembree itself for the treatment of uterine fibroids. At least if that was holding up the approval. Myfembree received FDA approval in early August, and the label looks good and should not hold the promotion back relative to main competitor Orilissa/Oriahnn. However, if that was the hard part, the next is even harder – the commercialization of Myfembree in the large endometriosis market. I say that’s the harder part due to AbbVie’s complete failure in launching Orilissa/Oriahnn (which also goes by the generic name elagolix). I covered this in my April article, but it's a subject worth mentioning again and expanding a bit on. I would say the failure of Orilissa/Oriahnn has a lot to do with the lack of effort on AbbVie’s side. AbbVie went from being seemingly genuinely excited about the prospects of this drug in the large endometriosis and uterine fibroids market (AbbVie's CEO Gonzales said this in late 2018: "Elagolix is yet another compelling asset that represents a multibillion-dollar growth opportunity") to not even mentioning it anymore on earnings calls, and lately, to not even reporting quarterly sales. For the last two quarters, I had to calculate the sales based on royalties reported by AbbVie’s partner Neurocrine Biosciences (NBIX). And the situation is not pretty. Sales of Orilissa/Oriahnn flatlined in the high 30s last year and have declined to $27 million and $34 million in the first two quarters of 2022, respectively. Orilissa/Oriahnn sales growth (AbbVie Earnings reports, Neurocrine Biosciences earnings reports) First, Myovant is far more motivated than AbbVie to succeed. Orilissa is a tiny and largely irrelevant product to AbbVie, and it's a very important one for Myovant. Second, Myovant is not doing this alone, it's co-promoting the product with Pfizer. And third, we have seen evidence of the early commercial success of Myfembree compared to Oriahnn as Myfembree has already reached 51% total prescription market share and 57% new to brand share in the uterine fibroids market. This is a significant achievement this early in the launch and goes back to the first point – that Myfembree is a high-priority asset for Myovant and a low or no-priority asset for AbbVie. Myovant investor presentation But that's not to say I expect Myfembree to be a blockbuster product for Myovant. I just think it can do better – as already stated in my initial article, I expect annual sales of Myfembree to reach $400-500 million in 4-5 years. Orgovyx’s progress continues Net sales of Orgovyx grew 22% sequentially to $36 million in the fiscal Q1 2022 (calendar Q2 2022). Myovant investor presentation Approximately 3,500 new patients started treatment on Orgovyx in the quarter, reaching 18,000 cumulative patients since launch. Gross to nets remained within the previously stated range of low to mid-40s, though they were on the higher end of the range due to what management explained were “quarterly fluctuations.” Due to these fluctuations, the net price was a bit lower sequentially. But that meant the underlying volume growth was even better at 26% vs. the 22% sequential increase in net sales. Should gross to nets go back to the mid-point of the expected range, net price should be a slight tailwind in the second half of the year.Seeking Alpha • Aug 09
Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
SVB Securities has upgraded Myovant Securities (NYSE:MYOV) to outperform from market perform due to the recent approval of Myfembree for pain associated with endometriosis and tailwinds from an existing approval in in uterine fibroids. The firm also upgraded the price target to $23 from $12 (~47% upside based on Friday's close). Analyst Roanna Ruiz said that the Myfembree (relugolix, estradiol, and norethindrone acetate) endometriosis approval is "a nice clearing event that solidifies Myfembree’s competitive once-daily clinical profile vs. AbbVie's (ABBV) Orlissa/Oriahnn." She added that the approval came with no safety signals or amendments. Ruiz noted that Myovant (MYOV) is becoming appealing to more investors as it has commercial growth through multiple products "without risky binary events like late-stage like late-stage clinical trial readouts." She added that after the U.S. FDA issued a deficiency letter and action date delay for the endometriosis indication followed by approval, the agency may be more open to approving women's health drugs, "which is good news for Myovant's (MYOV) 2nd sNDA filing." Seeking Alpha contributor Edmund Ingham said that Myovant (MYOV) is a sell because the "valuation looks excessive."Seeking Alpha • Jul 27
Myovant stock gains ~6% after hours on Q1 revenue jump
Myovant Sciences (NYSE:MYOV) stock has gained 6.1% to $12.98 after hours on Wednesday, as the pharmaceutical company reported a huge jump in Q1 revenue and a narrower quarterly loss per share. MYOV said its Q1 revenue nearly tripled Y/Y to $116.49M, helped by a $50M upfront payment from Accord Healthcare under a licensing agreement signed in May between the two companies to introduce prostate cancer therapy Orgovyx in Europe. MYOV's product revenue also more than tripled Y/Y to $41.35M, as sales of Orgovyx and Myfembree, a drug to control heavy menstrual bleeding due to uterine fibroids, improved in the quarter. About 3.5K new patients started treatment with Orgovyx in Q1, while around 2.4K new patients started treatment with Myfembree. The company said cash, cash equivalents, marketable securities, and amounts available under its loan agreement with Sumitomo Pharma totaled $400M as of June 30, 2022. MYOV stock -21.5% YTD.Seeking Alpha • Jul 18
Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgovyx was approved in Europe. Myovant has also made commercial progress with Orgovyx delivering strong sequential growth. The PDUFA date for Myfembree next month is the most important near-term catalyst for MYOV stock. Shares of Myovant Sciences (MYOV) rose 12% since my previous article, a period during which the major indices and biotech stocks declined. However, the company made commercial and regulatory progress since my previous update and it also found a partner for Orgovyx in Europe. Overall, the situation is trending in the right direction and the main obstacle in the near term is the FDA's decision on the sNDA for Myfembree for the treatment of endometriosis. Ycharts.com PDUFA date extended in the U.S. for Myfembree, Orgovyx approved in Europe When the stock plunged in April due to the deficiencies identified by the FDA for the sNDA submission for Myfembree for the treatment of moderate to severe pain associated with endometriosis, there was a clear possibility the FDA would issue a complete response letter the next month. And then, in early May, Myovant and partner Pfizer (PFE) announced that the FDA has extended the review period by three months and that the new PDUFA date is August 6, 2022. They said that the FDA required additional time to review additional information it requested from the companies regarding bone mineral density. On the earnings call, management clarified that this was part of the regular review process and that they are not sure whether the request is related to the deficiencies identified by the agency the month before, but it is plausible that this is the case. Similar to the approved Orilissa which is in the same class of drugs, Myfembree does have a negative impact on bone mineral density, but this is an issue that can be addressed with appropriate product labeling, as it was in the case of Orilissa but also already in Myfembree's case as it is already approved for the treatment of uterine fibroids. There was a clear regulatory win as well - the European Commission has approved Orgovyx for the treatment of adult patients with advanced hormone-sensitive prostate cancer. Myovant was able to quickly take advantage of the approval to sign an exclusive license agreement with Accord Healthcare to commercialize Orgovyx in the EU, UK, Switzerland and Turkey, and with the right of first negotiation if Myovant decides to enter into licensing arrangements in the Middle East, Africa, and India. Myovant received $50 million upfront and is eligible to receive commercial launch, sales-based and other milestones totaling $90.5 million, of which $15 million are near-term milestones, and tiered royalties on net sales from the high-teens to mid-twenties. Launch in Europe is expected later this year. This is a nice deal for Myovant, and ensures Orgovyx has a commercial presence in Europe. Commercial progress - good growth in the first quarter The fiscal Q4 2021 quarter (calendar Q1 2022) was a very decent quarter for Myovant's commercial operations. Both Orgovyx and Myfembree registered strong sequential patient growth that was impacted by the seasonal headwinds - increased discounts and lower refill rates in the early part of the calendar year due to the annual resets of Medicare Part D plans and payer deductibles. Orgovyx net sales in the U.S. increased 21% to $29.4 million with approximately 3,500 new patients, bringing the cumulative number of patients to approximately 14,500. There is still a very large market to penetrate into - approximately 300,000 patients in the U.S. every year. For fiscal 2022, management expects gross to net discounts to expand from approximately 40% to the low to mid-40s, a slight pricing headwind for the year, assuming no list price increases. Myfembree net sales were down sequentially despite the nearly doubling of commercial demand from the calendar Q4 2021. The offsetting factor is the significantly lower net price due to the January reset of commercial payer deductibles which forced the company to increase copay support to patients. The net price should improve in the following quarters, and Myfembree has made good progress in this small market (in terms of net sales) as its new to brand prescription share has already reached 59% by the end of the quarter, just 8 months into the launch. However, this is more a reflection of the low revenue base of the uterine fibroids market for the class and competitor AbbVie's (ABBV) evident lack of effort around Orilissa and Oriahnn. It is also worth noting that Myovant is actually growing this category rather than taking patients from AbbVie - the GnRH antagonist market has grown 137% since the launch of Myfembree last year. Myovant Sciences Presentation분석 기사 • Apr 28
Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Shareholders in Myovant Sciences Ltd. ( NYSE:MYOV ) may be thrilled to learn that the analysts have just delivered a...Seeking Alpha • Apr 26
Myovant: Poised To Overcome Regulatory Issues
The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix will ultimately gain approval for endometriosis (perhaps in either Q3 or Q4 this year). Already marketed for two indications (i.e., advanced prostate cancer and uterine fibroids), you can expect relugolix sales to ramp up steadily and surely toward the blockbuster range.Seeking Alpha • Apr 13
Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Shares of Myovant Sciences plunged this week after a regulatory setback for Myfembree. No reasons were provided by the FDA yet, and the deficiency letter comes as a big surprise. Orgovyx in advanced prostate cancer remains the key revenue growth driver for the company. Myovant is now trading at attractive levels and can deliver upside even if Myfembree is not approved for the treatment of endometriosis.Seeking Alpha • Mar 26
Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Supplemental New Drug Application of MYFEMBREE for pain associated with endometriosis has been submitted to FDA; PDUFA date of May 6, 2022 has been set. If FDA approval of MYFEMBREE for pain associated with endometriosis is achieved, then Myovant would be eligible to earn $100 million as a milestone payment from Pfizer. CHMP has given positive opinion for ORGOVYX for treatment of hormone-sensitive prostate cancer; European opinion expected mid 2022. The endometriosis sector across the seven major markets is expected to grow to $2.91 billion by 2030.Seeking Alpha • Jan 02
Myovant: Catalysts Powering More Upside
Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental advancements that signal much more upsides going into New Year 2022. The partial clinical hold for the SERENE trial is recently removed by the FDA. Orgovyx is poised to gain approval in Europe by mid-year 2022.분석 기사 • May 14
Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
Myovant Sciences Ltd. ( NYSE:MYOV ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Myovant Sciences Ltd. ( NYSE:MYOV ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Feb 13
Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
It's been a sad week for Myovant Sciences Ltd. ( NYSE:MYOV ), who've watched their investment drop 11% to US$21.38 in...분석 기사 • Jan 12
Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Myovant Sciences Ltd. ( NYSE:MYOV ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Dec 23
Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...분석 기사 • Nov 18
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 3/31/2025 | 618 | -74 | N/A | N/A | 2 |
| 3/31/2024 | 555 | -76 | N/A | N/A | 3 |
| 3/31/2023 | 418 | -153 | N/A | N/A | 2 |
| 12/31/2022 | 379 | -184 | -271 | -270 | N/A |
| 9/30/2022 | 333 | -190 | -260 | -259 | N/A |
| 6/30/2022 | 306 | -166 | -232 | -231 | N/A |
| 3/31/2022 | 231 | -206 | -270 | -269 | N/A |
| 12/31/2021 | 198 | -228 | -263 | -261 | N/A |
| 9/30/2021 | 145 | -238 | 403 | 405 | N/A |
| 6/30/2021 | 67 | -284 | 318 | 319 | N/A |
| 3/31/2021 | 59 | -255 | 369 | 371 | N/A |
| 12/31/2020 | 35 | -239 | 443 | 444 | N/A |
| 9/30/2020 | 33 | -250 | -198 | -197 | N/A |
| 6/30/2020 | 33 | -254 | -217 | -216 | N/A |
| 3/31/2020 | N/A | -289 | -222 | -221 | N/A |
| 12/31/2019 | N/A | -299 | -256 | -255 | N/A |
| 9/30/2019 | N/A | -284 | -252 | -250 | N/A |
| 6/30/2019 | N/A | -279 | -247 | -246 | N/A |
| 3/31/2019 | N/A | -274 | -225 | -224 | N/A |
| 12/31/2018 | N/A | -247 | -207 | -206 | N/A |
| 9/30/2018 | N/A | -218 | -176 | -175 | N/A |
| 6/30/2018 | N/A | -182 | -136 | -135 | N/A |
| 3/31/2018 | N/A | -143 | -118 | -117 | N/A |
| 12/31/2017 | N/A | -117 | -94 | -93 | N/A |
| 9/30/2017 | N/A | -83 | -70 | -69 | N/A |
| 6/30/2017 | N/A | -88 | -46 | -45 | N/A |
| 3/31/2017 | N/A | -83 | -19 | -18 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: MYOV 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.1%)보다 빠른 성장으로 간주됩니다.
수익 vs 시장: MYOV (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: MYOV 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: MYOV 의 수익(연간 27.6%)이 US 시장(연간 11.8%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: MYOV 의 수익(연간 27.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: MYOV의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2023/03/12 23:51 |
| 종가 | 2023/03/09 00:00 |
| 수익 | 2022/12/31 |
| 연간 수익 | 2022/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Myovant Sciences Ltd.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Skorney | Baird |
| Mohit Bansal | Citigroup Inc |
| Jason Butler | Citizens JMP Securities, LLC |